PNET prognosis and survival — why this outlook is different

If you have searched for a pancreatic cancer survival figure since the diagnosis, almost everything you found was about a different disease. Most pancreatic cancer is ductal adenocarcinoma, which starts in the ducts and tends to grow quickly. A pancreatic neuroendocrine tumour — a PNET — starts in the hormone-producing islet cells, usually grows far more slowly, is staged on its own system and is treated on an entirely separate track. Pancreatic neuroendocrine tumours (PNET) explained sets out what the diagnosis itself means.

So PNET prognosis is a genuinely different question with a genuinely different answer. This is still a cancer and it still needs a plan and a specialist. But for most people with a well-differentiated neuroendocrine tumour the outlook is considerably better than the figures that appear when you type the words pancreatic cancer into a search box — often measured in years, and frequently in many years, including for people whose tumour has already reached the liver.

Four things make a published number misleading here. It is usually pooled: cancer registries that report pancreatic cancer as one disease bury a small number of neuroendocrine tumours inside a far larger number of adenocarcinomas, and the headline follows the majority. It is averaged across grades: a slow, low-grade tumour and a poorly differentiated neuroendocrine carcinoma can sit inside the same line, although they behave nothing alike. It is historical: any survival figure needs years of follow-up before it can be calculated, so it describes people treated before the current options existed — and neuroendocrine care has changed a great deal in that window. And it describes a group, not a person: your grade, your stage, whether an operation is possible and how the tumour behaves on your own scans all sit outside the average.

None of that makes the figures worthless. It makes them a starting point for a specific conversation rather than an answer on their own. The same reasoning applies to the ordinary pancreatic numbers, and pancreatic cancer survival by stage — how to read the numbers takes that apart in detail. For the whole picture from diagnosis onwards, the complete pancreatic cancer guide covers the rest.

• Does the report say neuroendocrine tumour or adenocarcinoma? Read the pathology wording itself, not how the diagnosis was summarised in the corridor. If it says neuroendocrine, adenocarcinoma figures do not apply to you at all.
• Well differentiated or poorly differentiated, and what grade? Ask for both words. They are the two findings that shape the outlook and the treatment more than anything else on the page.
• Is it functioning or non-functioning? If a hormone is being produced, controlling the symptoms it causes becomes part of the plan alongside controlling the tumour itself.
• Is an operation possible now, or could it become possible? Ask explicitly. The answer at diagnosis is not always the final answer, and it is worth revisiting after treatment has had time to work.
• What is the plan if it is left alone for now? Watchful surveillance is a legitimate plan for some small, low-grade tumours, and it should come with a written scan interval rather than a vague promise to keep an eye on it.
• What are the treatment options if it does need treating? Pancreatic cancer treatment in Hyderabad sets out what is available and who delivers each part of it.

1. 1

   Confirm the tumour type on paper

   The pathology report decides whether any adenocarcinoma figure applies to you. Tissue is usually taken through endoscopic ultrasound with a fine-needle sample.

   Biopsy coordinated with specialist endoscopy partners
2. 2

   Establish differentiation and grade

   The pathologist reports how closely the cells resemble normal islet tissue and how actively they are dividing. These two findings carry more prognostic weight than anything else available at diagnosis.

   Graded by the reporting pathologist; read with you at CION
3. 3

   Map where it has and has not reached

   A dedicated pancreatic-protocol contrast CT or an MRI shows the tumour, the vessels around it, the nodes and the liver. Bloods are taken, with a marker such as chromogranin A where it is going to be useful to follow.

   Ordered and reported in-house at CION
4. 4

   Add a receptor scan only where it changes something

   A DOTATATE PET scan shows whether the tumour carries the receptors that make certain treatments possible. It is requested when the answer will change the plan, not routinely.

   DOTATATE PET and PET-CT coordinated with partner imaging centres
5. 5

   Review the case as a team

   Imaging, pathology and your general health are discussed together at the tumour board, so the plan reflects what medical oncology, radiation oncology and the surgical partners each believe is achievable.

   Tumour board at CION
6. 6

   Answer the outlook question honestly

   We tell you what the published figures describe, which parts apply to you and which do not, and what would change the answer. We will not invent a number, and we will not present a group average as your forecast.

   Free 45-minute consultation

Saying this early saves an awkward conversation later. Your first consultation is free and lasts 45 minutes, and it is a proper review of your reports rather than a booking appointment.

Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology for neuroendocrine tumours, including somatostatin-analogue-class therapy, targeted oral systemic treatment and chemotherapy where the tumour is poorly differentiated; radiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI and blood markers; genetic counselling where an inherited syndrome is suspected; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and the long surveillance follow-up that a neuroendocrine tumour usually needs.

Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: all pancreatic surgery, whether that is shelling out a small tumour, removing the tail of the pancreas or a full Whipple procedure; liver-directed surgical treatment; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we take part in the decisions, and we tell you in advance where each one happens and who will invoice you. We do not describe them as our own theatre, endoscopy or nuclear-medicine lists, because they are not.

A neuroendocrine tumour is a cancer, and pretending otherwise would not help you. It needs a specialist, a plan and follow-up that does not lapse. But the honest version of the outlook is far less bleak than the one you will have read on your first evening of searching.

Cure is genuinely possible when the tumour is confined and can be removed completely. Where it cannot be removed, the aim shifts to controlling it — and neuroendocrine tumours are unusually amenable to being controlled for a long time, which is why people ask about pnet life expectancy and get an answer measured in years rather than months. Liver deposits do not close the conversation here as they would elsewhere; they change which treatments come first. Small, low-grade, non-functioning tumours found by chance may be watched rather than treated at all, on a written scan schedule.

The practical consequence is that this becomes a long relationship rather than a single crisis. Scans continue for years. Some appointments will bring a change of treatment and most will bring nothing new, which is the result you want. Scan anxiety before each one is close to universal and worth naming rather than enduring silently — our psycho-oncology and supportive-care team can help with it directly, and it is a reasonable thing to ask for.

Medical disclaimer: This page explains what prognosis in a pancreatic neuroendocrine tumour actually depends on, and is reviewed by a CION medical oncologist with reference to NCCN guidance on neuroendocrine tumours and the WHO classification. It is general information and deliberately states no survival figure, because no published figure describes an individual; your own outlook depends on differentiation, grade, stage, resectability and your general health, and should be discussed with your treating team. Systemic therapy for neuroendocrine tumours, radiation and SBRT, imaging and blood-marker ordering and reporting, genetic counselling, nutrition and enzyme support, pain relief, psycho-oncology and long-term surveillance are delivered by CION; all pancreatic and liver-directed surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.